查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2153430

全球皮膚科藥物市場規模、佔有率、趨勢和成長分析報告（2026-2034）

Global Dermatologicals Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球皮膚科藥品市場預計將從2025年的296.1億美元成長至2034年的760.5億美元，2026年至2034年的複合年成長率（CAGR）為11.05%。此市場的成長主要得益於醫療保健領域整體皮膚疾病及相關病症治療藥物的持續需求。皮膚科產品包括處方藥、外用藥物以及其他用於治療痤瘡、濕疹、乾癬、真菌感染疾病和發炎性皮膚病等疾病的治療製劑。人們對皮膚健康的日益關注、就診皮膚科的頻率增加以及對慢性皮膚病的認知不斷提高，都推動了這一需求的成長。此外，消費者和醫療保健專業人員越來越關注皮膚疾病對舒適度、日常活動和生活品質的影響，這也促使人們持續投資於有效的治療方法。

市場成長主要得益於皮膚病學研究的進展、標靶治療的開發以及局部和全身性治療藥物的日益普及。製藥公司正積極推動發炎性和自體免疫皮膚病新藥的研究，包括生物製藥和其他針對特定疾病路徑的療法。製劑技術的進步使生產商能夠開發出劑量特性各異、用藥需求不同的產品。學名藥的出現也提高了價格敏感型市場中治療藥物的可及性。此外，遠距皮膚科會診和數位化諮詢服務使部分患者更容易獲得專家的指導，從而可能實現更早的評估和更持續的治療。

該市場的未來前景取決於醫藥領域的持續創新、疾病管理水準的提高以及更個人化治療方案的發展。生物製藥、局部給藥和標靶治療的進步可望拓寬慢性病和難治性疾病患者的治療選擇。如果經過適當檢驗，數位化皮膚病學工具和人工智慧影像分析有望支持臨床評估和後續觀察。對治療依從性和以患者為中心的護理日益成長的關注也可能推動更便捷劑型的開發。然而，治療成本、副作用、監管要求以及皮膚科服務取得方面的差異可能會影響市場發展。為了實現永續成長，持續的研發和負責任的治療實踐仍然至關重要。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球皮膚科藥物市場：依疾病分類

  • 市場分析、洞察與預測
  • 粉刺
  • 皮膚炎
  • 銀屑病
  • 皮膚癌
  • 酒糟
  • 脫髮症
  • 其他

第5章 全球皮膚科藥物市場：按類型分類

  • 市場分析、洞察與預測
  • 處方藥
  • 非處方藥

第6章 全球皮膚科藥物市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 局部行政部門
  • 口服
  • 腸外給藥

第7章 全球皮膚科藥物市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • AbbVie
    • Galderma
    • Johnson & Johnson
    • L'Oreal
    • Sanofi
    • Novartis
    • Eli Lilly
    • Bristol Myers Squibb
    • Amgen
    • UCB
    • Sun Pharma
    • Teva Pharmaceuticals
    • Bausch Health
    • Almirall
    • LEO Pharma
    • Regeneron
    • Incyte
    • Arcutis Biotherapeutics
    • Pfizer
    • Bayer
簡介目錄
Product Code: VMR11217673

The global dermatologicals market size is expected to reach USD 76.05 Billion in 2034 from USD 29.61 Billion in 2025, growing at a CAGR of 11.05% during 2026-2034.This market is growing as demand for treatments addressing skin diseases and related conditions continues across healthcare settings. Dermatological products include prescription medicines, topical treatments, and other therapeutic formulations used for conditions such as acne, eczema, psoriasis, fungal infections, and inflammatory skin disorders. Increasing awareness of skin health, improved access to dermatology consultations, and greater recognition of chronic skin conditions are supporting demand. Consumers and healthcare professionals are also paying more attention to the impact of skin disorders on comfort, daily activities, and quality of life, encouraging continued investment in effective treatment options.

Market growth is driven by advances in dermatology research, the development of targeted therapies, and expanding availability of topical and systemic treatments. Pharmaceutical companies are investigating new medicines for inflammatory and autoimmune skin disorders, including biologic therapies and other treatments that target specific disease pathways. Improvements in formulation technologies are helping manufacturers develop products with different delivery characteristics and patient-use requirements. Generic medicines also contribute to treatment availability across price-sensitive markets. Furthermore, teledermatology and digital consultation services are helping some patients access specialist guidance, potentially supporting earlier evaluation and better continuity of care.

The future prospects of this market will depend on continued pharmaceutical innovation, improved disease management, and the development of more personalized treatment approaches. Advances in biologics, topical drug delivery, and targeted medicines may expand options for patients with chronic or difficult-to-treat conditions. Digital dermatology tools and AI-assisted image analysis could support clinical assessment and follow-up when appropriately validated. Growing interest in treatment adherence and patient-centered care may also encourage the development of convenient formulations. However, treatment costs, adverse effects, regulatory requirements, and differences in access to dermatology services will influence market development. Continued research and responsible treatment practices will remain important for sustained growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Disease

  • Acne
  • Dermatitis
  • Psoriasis
  • Skin Cancer
  • Rosacea
  • Alopecia
  • Others

By Type

  • Prescription-based drugs
  • Over-the-counter drugs

By Route of Administration

  • Topical Administration
  • Oral Administration
  • Parenteral Administration

COMPANIES PROFILED

  • AbbVie, Galderma, Johnson & Johnson, L'Oreal, Sanofi, Novartis, Eli Lilly, Bristol Myers Squibb, Amgen, UCB, Sun Pharma, Teva Pharmaceuticals, Bausch Health, Almirall, LEO Pharma, Regeneron, Incyte, Arcutis Biotherapeutics, Pfizer, Bayer

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL DERMATOLOGICALS MARKET: BY DISEASE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Disease
  • 4.2. Acne Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Dermatitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Psoriasis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Skin Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Rosacea Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Alopecia Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DERMATOLOGICALS MARKET: BY TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Type
  • 5.2. Prescription-based drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Over-the-counter drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DERMATOLOGICALS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Topical Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Oral Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Parenteral Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL DERMATOLOGICALS MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Disease
    • 7.2.2 By Type
    • 7.2.3 By Route Of Administration
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Disease
    • 7.3.2 By Type
    • 7.3.3 By Route Of Administration
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Spain
    • 7.3.9 Russia
    • 7.3.10 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Disease
    • 7.4.2 By Type
    • 7.4.3 By Route Of Administration
    • 7.4.4 China
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 India
    • 7.4.8 Australia
    • 7.4.9 South East Asia
    • 7.4.10 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Disease
    • 7.5.2 By Type
    • 7.5.3 By Route Of Administration
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Disease
    • 7.6.2 By Type
    • 7.6.3 By Route Of Administration
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL DERMATOLOGICALS INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 AbbVie
    • 9.2.2 Galderma
    • 9.2.3 Johnson & Johnson
    • 9.2.4 L'Oreal
    • 9.2.5 Sanofi
    • 9.2.6 Novartis
    • 9.2.7 Eli Lilly
    • 9.2.8 Bristol Myers Squibb
    • 9.2.9 Amgen
    • 9.2.10 UCB
    • 9.2.11 Sun Pharma
    • 9.2.12 Teva Pharmaceuticals
    • 9.2.13 Bausch Health
    • 9.2.14 Almirall
    • 9.2.15 LEO Pharma
    • 9.2.16 Regeneron
    • 9.2.17 Incyte
    • 9.2.18 Arcutis Biotherapeutics
    • 9.2.19 Pfizer
    • 9.2.20 Bayer